[{"id":"8569ee21-bd18-4f85-b00e-93a8016165f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06962254","created_at":"2025-09-07T01:31:17.766Z","updated_at":"2025-09-07T01:31:17.766Z","phase":"Phase 1","brief_title":"Imatinib and Trametinib for KRAS-mutated Solid Tumor","source_id_and_acronym":"NCT06962254","lead_sponsor":"China Medical University Hospital","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/10/2025","start_date":" 05/10/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-05-08"},{"id":"58d26922-dd62-4243-8588-89fbcbf5d940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152995","created_at":"2021-03-24T14:59:26.184Z","updated_at":"2025-02-25T12:26:08.615Z","phase":"Phase 2","brief_title":"Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer","source_id_and_acronym":"NCT02152995","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • NRAS • HRAS • EGF","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61","tags":["HER-2 • KRAS • BRAF • NRAS • HRAS • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/14/2014","start_date":" 08/14/2014","primary_txt":" Primary completion: 08/25/2021","primary_completion_date":" 08/25/2021","study_txt":" Completion: 01/25/2026","study_completion_date":" 01/25/2026","last_update_posted":"2025-02-24"},{"id":"6645a7c8-abbe-46a7-be97-ec48de55bd51","acronym":"","url":"https://clinicaltrials.gov/study/NCT02070549","created_at":"2021-01-18T09:32:22.387Z","updated_at":"2025-02-25T15:10:06.793Z","phase":"Phase 1","brief_title":"Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction","source_id_and_acronym":"NCT02070549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2025-02-13"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"0829dd6e-d56c-4a78-8e9f-bd6b6b2da23c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02079740","created_at":"2021-01-18T09:35:19.928Z","updated_at":"2025-02-25T15:33:04.083Z","phase":"Phase 1/2","brief_title":"Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02079740","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • NRAS • BCL2L2","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS • BCL2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/26/2014","start_date":" 03/26/2014","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-11"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"8bd4b6dd-9110-48f1-9cd7-f15472829753","acronym":"","url":"https://clinicaltrials.gov/study/NCT02642042","created_at":"2021-01-18T12:51:12.920Z","updated_at":"2025-02-25T16:36:42.163Z","phase":"Phase 2","brief_title":"Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02642042","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • TP53 • STK11","pipe":" | ","alterations":" TP53 mutation • KRAS mutation","tags":["KRAS • TP53 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • docetaxel • omipalisib (GSK2126458)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/18/2016","start_date":" 07/18/2016","primary_txt":" Primary completion: 05/15/2019","primary_completion_date":" 05/15/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"bc0153fa-3f27-4593-8ca6-41236ea47eb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03501368","created_at":"2021-01-18T17:13:51.868Z","updated_at":"2025-02-25T15:43:02.794Z","phase":"Phase 1","brief_title":"Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma","source_id_and_acronym":"NCT03501368","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 10/28/2022","primary_completion_date":" 10/28/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-12-04"},{"id":"9f5673ee-f7a4-40b1-ace8-59a97f2bd04f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990196","created_at":"2021-01-18T09:04:40.027Z","updated_at":"2025-02-25T13:10:58.081Z","phase":"Phase 2","brief_title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","source_id_and_acronym":"NCT01990196","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VIM • CDH2","pipe":" | ","alterations":" VIM expression","tags":["VIM • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • dasatinib • Xtandi (enzalutamide) • Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/23/2014","start_date":" 09/23/2014","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-10-01"},{"id":"96e420b5-20d6-444c-80a7-976e582c147d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05440942","created_at":"2022-07-01T21:55:26.997Z","updated_at":"2025-02-25T15:54:31.335Z","phase":"Phase 1","brief_title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT05440942","lead_sponsor":"Peter Hosein, MD","biomarkers":" TMB • BRCA1 • BRCA2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-09-11"},{"id":"7c689d51-0e44-4011-9164-a6ec2c89625e","acronym":"COMBI-i","url":"https://clinicaltrials.gov/study/NCT02967692","created_at":"2021-01-17T17:17:14.303Z","updated_at":"2024-07-02T16:34:25.889Z","phase":"Phase 3","brief_title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","source_id_and_acronym":"NCT02967692 - COMBI-i","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF V600","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 569","initiation":"Initiation: 02/17/2017","start_date":" 02/17/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2024-06-14"},{"id":"5822d0ef-f563-4c59-8353-4d50af33551c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06456138","created_at":"2024-06-15T04:06:37.221Z","updated_at":"2025-02-25T15:45:39.816Z","phase":"Phase 1/2","brief_title":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","source_id_and_acronym":"NCT06456138","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-13"},{"id":"7ae39bae-f74c-4bd9-bb9c-b0ac08141f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04892017","created_at":"2021-05-19T15:52:38.986Z","updated_at":"2024-07-02T16:34:26.607Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors","source_id_and_acronym":"NCT04892017","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-13"},{"id":"1f12d403-2fb1-4336-8060-02027bae83cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04294160","created_at":"2021-01-18T20:50:10.771Z","updated_at":"2024-07-02T16:34:27.442Z","phase":"Phase 1","brief_title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","source_id_and_acronym":"NCT04294160","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 10/11/2024","primary_completion_date":" 10/11/2024","study_txt":" Completion: 10/11/2024","study_completion_date":" 10/11/2024","last_update_posted":"2024-06-11"},{"id":"9ab34498-035f-40c4-a842-cade8ef43a5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04417621","created_at":"2021-01-18T21:17:23.302Z","updated_at":"2024-07-02T16:34:27.392Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT04417621","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" NRAS mutation • BRAF V600","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Kisqali (ribociclib) • naporafenib (ERAS-254) • rineterkib (LTT462)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-06-11"},{"id":"69c0c3d7-d12e-4846-a87b-98d5f38f2dcd","acronym":"SJDAWN","url":"https://clinicaltrials.gov/study/NCT03434262","created_at":"2021-01-18T16:56:26.116Z","updated_at":"2025-02-25T15:54:00.489Z","phase":"Phase 1","brief_title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","source_id_and_acronym":"NCT03434262 - SJDAWN","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 05/24/2024","study_completion_date":" 05/24/2024","last_update_posted":"2024-05-31"},{"id":"02eaf617-0513-44fc-bea7-b3c0c01ecd8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849662","created_at":"2023-05-09T14:04:18.433Z","updated_at":"2024-07-02T16:35:02.520Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT05849662","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" KRAS • NRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation","tags":["KRAS • NRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-20"},{"id":"cfc2985f-51c4-4ab9-8232-962b73ff7481","acronym":"NCI-2013-02103","url":"https://clinicaltrials.gov/study/NCT01989585","created_at":"2021-01-18T09:04:22.279Z","updated_at":"2024-07-02T16:35:03.325Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","source_id_and_acronym":"NCT01989585 - NCI-2013-02103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • BCL2","pipe":" | ","alterations":" BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K","tags":["PTEN • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/24/2014","start_date":" 03/24/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"},{"id":"bc138b32-b1a5-4fc9-8fd6-616343a12a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439279","created_at":"2021-01-18T21:22:11.456Z","updated_at":"2024-07-02T16:35:04.931Z","phase":"Phase 2","brief_title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)","source_id_and_acronym":"NCT04439279","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF fusion","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 03/18/2019","primary_completion_date":" 03/18/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-08"},{"id":"dd849209-d63d-4be8-8b30-8630c3f63b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT05874414","created_at":"2023-05-24T18:06:43.955Z","updated_at":"2024-07-02T16:35:05.935Z","phase":"Phase 1/2","brief_title":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma","source_id_and_acronym":"NCT05874414","lead_sponsor":"Genfit","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • ezurpimtrostat (GNS561)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-03"},{"id":"1889266c-a5ce-4ecd-95ad-5b5f5df04c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT05668585","created_at":"2022-12-30T14:58:29.873Z","updated_at":"2024-07-02T16:35:06.423Z","phase":"Phase 1/2","brief_title":"A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors","source_id_and_acronym":"NCT05668585","lead_sponsor":"C4 Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • BRAF V600","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mekinist (trametinib) • CFT1946"],"overall_status":"Recruiting","enrollment":" Enrollment 206","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 03/11/2027","primary_completion_date":" 03/11/2027","study_txt":" Completion: 04/11/2027","study_completion_date":" 04/11/2027","last_update_posted":"2024-05-02"}]